Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Experimental drug

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    552 result(s) found for: Experimental drug. Displaying page 28 of 28.
    «« First « Previous 20  21  22  23  24  25  26  27  28 
    EudraCT Number: 2010-019387-37 Sponsor Protocol Number: AMAG-FER-CKD-251 Start Date*: 2011-05-11
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subje...
    Medical condition: Dialysis dependent Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Temporarily Halted) GB (Prematurely Ended) HU (Completed) ES (Completed) RO (Ongoing) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019550-40 Sponsor Protocol Number: AMAG-FER-CKD-253 Start Date*: Information not available in EudraCT
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) HU (Completed) ES (Completed) RO (Temporarily Halted) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001192-39 Sponsor Protocol Number: P11-1 Start Date*: 2012-01-26
    Sponsor Name:Dendreon Corporation
    Full Title: AN OPEN-LABEL STUDY OF SIPULEUCEL-T IN EUROPEAN MEN WITH METASTATIC, CASTRATE RESISTANT PROSTATE CANCER
    Medical condition: metastatic castrate resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036910 Prostate cancer NOS LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036916 Prostate cancer stage D LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001605-14 Sponsor Protocol Number: CCR4309 Start Date*: 2015-07-21
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A Randomised, double-blind, placebo controlled, multi-centre phase II study to assess the Efficacy and safety of 2nd line Olaparib in combination with Paclitaxel, in Western patients with advanced ...
    Medical condition: Advanced Gastric and Gastro-oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017760 Gastric cancer NOS LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017768 Gastric cancer stage IV without metastases LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066350 Adenocarcinoma of the gastrooesophageal junction LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017766 Gastric cancer stage IV NOS LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061967 Gastric cancer stage IV PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017767 Gastric cancer stage IV with metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003170-27 Sponsor Protocol Number: GEICAM/2013-02 Start Date*: 2013-11-21
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: Phase III study of Palbociclib (PD-0332991) in combination with Exemestane versus chemotherapy (capecitabine) in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patient...
    Medical condition: Patients with hormonal receptor positive and HER2 negative MBC who are resistant to prior NSAI therapy.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) AT (Completed) HU (Completed) LV (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007087-17 Sponsor Protocol Number: A0221045 Start Date*: 2008-06-13
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK
    Full Title: A 24-WEEK, MULTICENTRE TRIAL, COMPRISING A 12-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE FOLLOWED BY A 12-WEEK OPEN-LABEL PHASE, TO EVALUATE THE EFFICACY AND SAFETY OF...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence (Some patients will also have urgency urinary incontinence (UUI)).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) GB (Completed) BE (Completed) SK (Completed) AT (Completed) DE (Completed) DK (Completed) PT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-018579-12 Sponsor Protocol Number: SPD503-316 Start Date*: 2011-01-26
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10068451 ADHD, combined type LLT
    14.1 10037175 - Psychiatric disorders 10068453 ADHD, predominantly inattentive type LLT
    14.1 10037175 - Psychiatric disorders 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.1 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Prematurely Ended) FR (Completed) ES (Completed) SE (Completed) IE (Completed) AT (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005357-29 Sponsor Protocol Number: WA20500 Start Date*: 2008-05-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephrit...
    Medical condition: Lupus Nephritis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) PT (Prematurely Ended) SE (Completed) PL (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019501-41 Sponsor Protocol Number: MPD-RC112 Start Date*: 2012-02-15
    Sponsor Name:CONSORZIO MARIO NEGRI SUD
    Full Title: Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia
    Medical condition: High Risk Polycythemia Vera or High Risk Essential Thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) SE (Ongoing) GB (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005063-34 Sponsor Protocol Number: CL1-11-040 Start Date*: 2009-09-14
    Sponsor Name:NPS Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP 558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)] for the Treatment of Adults with Hypoparathyr...
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021041 Hypoparathyroidism LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) BE (Completed) GB (Completed) IT (Completed) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-019765-28 Sponsor Protocol Number: SP0993 Start Date*: 2011-02-08
    Sponsor Name:UCB BIOSCIENCES GmbH
    Full Title: A MULTICENTER, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, POSITIVE CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) TO CONTROLLED RELEASE CARBAMAZEPINE (400 TO 1200M...
    Medical condition: Epilepsy, partial onset or generalised tonic-clonic seizures.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) FI (Completed) SE (Completed) HU (Completed) ES (Completed) PT (Completed) PL (Completed) SK (Completed) GB (Completed) GR (Completed) IT (Completed) LV (Completed) LT (Completed) BG (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-004471-13 Sponsor Protocol Number: PM1183-C-008-21 Start Date*: 2022-08-03
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relaps...
    Medical condition: Small Cell Lung Cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 20  21  22  23  24  25  26  27  28 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 26 00:07:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA